These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 26188848)

  • 1. The potential of clofarabine in MLL-rearranged infant acute lymphoblastic leukaemia.
    Stumpel DJ; Schneider P; Pieters R; Stam RW
    Eur J Cancer; 2015 Sep; 51(14):2008-21. PubMed ID: 26188848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Silencing of the tumor suppressor gene FHIT is highly characteristic for MLL gene rearranged infant acute lymphoblastic leukemia.
    Stam RW; den Boer ML; Passier MM; Janka-Schaub GE; Sallan SE; Armstrong SA; Pieters R
    Leukemia; 2006 Feb; 20(2):264-71. PubMed ID: 16357833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options.
    Stumpel DJ; Schneider P; van Roon EH; Boer JM; de Lorenzo P; Valsecchi MG; de Menezes RX; Pieters R; Stam RW
    Blood; 2009 Dec; 114(27):5490-8. PubMed ID: 19855078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absence of global hypomethylation in promoter hypermethylated Mixed Lineage Leukaemia-rearranged infant acute lymphoblastic leukaemia.
    Stumpel DJ; Schneider P; van Roon EH; Pieters R; Stam RW
    Eur J Cancer; 2013 Jan; 49(1):175-84. PubMed ID: 22921182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting.
    Schafer E; Irizarry R; Negi S; McIntyre E; Small D; Figueroa ME; Melnick A; Brown P
    Blood; 2010 Jun; 115(23):4798-809. PubMed ID: 20215641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypermethylation of specific microRNA genes in MLL-rearranged infant acute lymphoblastic leukemia: major matters at a micro scale.
    Stumpel DJ; Schotte D; Lange-Turenhout EA; Schneider P; Seslija L; de Menezes RX; Marquez VE; Pieters R; den Boer ML; Stam RW
    Leukemia; 2011 Mar; 25(3):429-39. PubMed ID: 21116279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia.
    Stam RW; den Boer ML; Meijerink JP; Ebus ME; Peters GJ; Noordhuis P; Janka-Schaub GE; Armstrong SA; Korsmeyer SJ; Pieters R
    Blood; 2003 Feb; 101(4):1270-6. PubMed ID: 12406912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of the let-7b microRNA pathway by DNA hypermethylation in infant acute lymphoblastic leukemia with MLL gene rearrangements.
    Nishi M; Eguchi-Ishimae M; Wu Z; Gao W; Iwabuki H; Kawakami S; Tauchi H; Inukai T; Sugita K; Hamasaki Y; Ishii E; Eguchi M
    Leukemia; 2013 Feb; 27(2):389-97. PubMed ID: 22918121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Romidepsin enhances the efficacy of cytarabine
    Cheung LC; Cruickshank MN; Hughes AM; Singh S; Chua GA; Ford J; Ferrari E; Oommen J; Malinge S; Lock RB; Kees UR; Kotecha RS
    Haematologica; 2019 Jul; 104(7):e300-e303. PubMed ID: 30679330
    [No Abstract]   [Full Text] [Related]  

  • 10. Azacitidine successfully maintained the second remission in an infant with KMT2A-rearranged acute lymphoblastic leukemia who relapsed after unrelated cord blood transplantation.
    Chijimatsu I; Imanaka Y; Tomizawa D; Eguchi M; Nishimura S; Karakawa S; Miki M; Hamamoto K; Fujita N
    Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28675638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
    Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
    Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia.
    Stam RW; Den Boer ML; Schneider P; de Boer J; Hagelstein J; Valsecchi MG; de Lorenzo P; Sallan SE; Brady HJ; Armstrong SA; Pieters R
    Blood; 2010 Feb; 115(5):1018-25. PubMed ID: 19965632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants.
    Driessen EM; van Roon EH; Spijkers-Hagelstein JA; Schneider P; de Lorenzo P; Valsecchi MG; Pieters R; Stam RW
    Haematologica; 2013 Jun; 98(6):937-44. PubMed ID: 23403319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations.
    Kerstjens M; Driessen EM; Willekes M; Pinhanços SS; Schneider P; Pieters R; Stam RW
    Oncotarget; 2017 Feb; 8(9):14835-14846. PubMed ID: 27588400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MLL-rearranged infant leukaemia: A 'thorn in the side' of a remarkable success story.
    Rice S; Roy A
    Biochim Biophys Acta Gene Regul Mech; 2020 Aug; 1863(8):194564. PubMed ID: 32376390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytosine arabinoside-metabolizing enzyme genes are underexpressed in children with MLL gene-rearranged acute lymphoblastic leukemia.
    Mata JF; Scrideli CA; Queiroz RP; Mori BO; Emerenciano M; Pombo-de-Oliveira MS; Tone LG
    Braz J Med Biol Res; 2006 Nov; 39(11):1417-23. PubMed ID: 17146554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The combination effects of bendamustine with antimetabolites against childhood acute lymphoblastic leukemia cells.
    Goto S; Goto H; Yokosuka T
    Int J Hematol; 2016 May; 103(5):572-83. PubMed ID: 26886449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytarabine-resistant leukemia cells are moderately sensitive to clofarabine in vitro.
    Yamauchi T; Uzui K; Nishi R; Shigemi H; Ueda T
    Anticancer Res; 2014 Apr; 34(4):1657-62. PubMed ID: 24692694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20/RNF40/WAC-H2B ubiquitination axis.
    Garrido Castro P; van Roon EHJ; Pinhanços SS; Trentin L; Schneider P; Kerstjens M; Te Kronnie G; Heidenreich O; Pieters R; Stam RW
    Leukemia; 2018 Feb; 32(2):323-331. PubMed ID: 28690313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MLL-Rearranged Acute Lymphoblastic Leukemia.
    El Chaer F; Keng M; Ballen KK
    Curr Hematol Malig Rep; 2020 Apr; 15(2):83-89. PubMed ID: 32350732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.